View cart “Humulin N” has been added to your cart.

Apidra SoloStar

$24.00

1 box (5 x 3 mL pens 100 U/mL)

Description

Dosage Forms & Strengths

injectable solution (as 10 mL vial and 3 mL cartridge for OptiClick SC device)

  • 100 units/mL

prefilled 3 mL pen (Solostar)

  • 100 units/mL

Diabetes Mellitus Type I or II

Indicated to improve glycemic control in adults and children with diabetes mellitus

Dosing considerations

  • Equipotent to regular human insulin (ie, elicits same glucose lowering effects on unit per unit basis) when administered IV
  • Insulin glulisine has a more rapid onset of action and a shorter duration of action than regular human insulin
  • Dosage must be individualized; blood glucose monitoring is essential in all patients receiving insulin therapy
  • Total daily insulin requirement may vary and is usually between 0.5-1 unit/kg/day
  • Insulin requirements may be altered during stress, major illness, or with changes in exercise, meal patterns, or coadministered drugs

SC injection

  • Administer within 15 minutes before a meal or within 20 minutes after starting a meal
  • When administered by SC injection, insulin glulisine should generally be used in regimens with an intermediate- or long-acting insulin
  • Administered by SC injection in the abdominal wall, thigh, or upper arm
  • Injection sites should be rotated within the same region (abdomen, thigh or upper arm) from one injection to the next to reduce the risk of lipodystrophy

Continuous SC injection (insulin pump)

  • May be administered by continuous SC infusion in the abdominal wall
  • Do not dilute or mix with any other insulin
  • Infusion sites should be rotated within the same region to reduce the risk of lipodystrophy
  • Insulin in the reservoir must be changed at least q48hr
  • Do not expose to temeratures >98.6 F (37 C)
  • Initial programming of the external insulin infusion pump should be based on the total daily insulin dose of the previous regimen
  • Malfunction of the insulin pump or infusion set, or handling errors or insulin degradation can rapidly lead to hyperglycemia, ketosis and diabetic ketoacidosis
  • See prescribing information for compatible insulin pumps

IV administration

  • May be administered IV while under medical supervision for glycemic control with close monitoring of blood glucose and serum potassium to avoid hypoglycemia and hypokalemia
  • When administered IV, use concentrations of 0.05-1 unit/mL in infusion systems using PVC bags
  • Stable only in 0.9% NaCl (normal saline)
  • Inspected visually for particulate matter and discoloration prior to administration
  • Do not administer insulin mixtures IV